These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

542 related items for PubMed ID: 27027878

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.
    Shimoda S, Sakamoto W, Hokamura A, Matsuo Y, Sekigami T, Ichimori S, Iwashita S, Ishii N, Otsu K, Yoshimura R, Nishiyama T, Sakaguchi M, Nishida K, Araki E.
    Endocr J; 2019 Aug 29; 66(8):745-752. PubMed ID: 31308304
    [Abstract] [Full Text] [Related]

  • 4. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
    Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH, Niskanen LK, BOOST: Intensify Premix I Investigators.
    Diabetes Care; 2014 Aug 29; 37(8):2084-90. PubMed ID: 24812432
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial.
    Kumar A, Franek E, Wise J, Niemeyer M, Mersebach H, Simó R.
    PLoS One; 2016 Aug 29; 11(10):e0163350. PubMed ID: 27760129
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).
    Hirsch IB, Franek E, Mersebach H, Bardtrum L, Hermansen K.
    Diabet Med; 2017 Feb 29; 34(2):167-173. PubMed ID: 26773446
    [Abstract] [Full Text] [Related]

  • 7. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
    Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, Romero E, Mersebach H, Dykiel P, Jorde R.
    Diabetes Care; 2011 Mar 29; 34(3):669-74. PubMed ID: 21285389
    [Abstract] [Full Text] [Related]

  • 8. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y, Andersen TH, Gall MA, Christiansen JS, BOOST: Intensify All Trial Investigators.
    Diabetes Res Clin Pract; 2015 Jan 29; 107(1):139-47. PubMed ID: 25498130
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
    Liu M, Gu W, Chen L, Li Y, Kuang H, Du J, Alvarez A, Lauand F, Souhami E, Zhang J, Xu W, Du Q, Mu Y, SoliD trial investigators.
    Diabetes Obes Metab; 2024 Sep 29; 26(9):3791-3800. PubMed ID: 38922731
    [Abstract] [Full Text] [Related]

  • 10. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
    Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM.
    Diabetes Care; 2013 Sep 29; 36(9):2536-42. PubMed ID: 23715753
    [Abstract] [Full Text] [Related]

  • 11. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
    Pan C, Gross JL, Yang W, Lv X, Sun L, Hansen CT, Xu H, Wagner R.
    Drugs R D; 2016 Jun 29; 16(2):239-49. PubMed ID: 27098525
    [Abstract] [Full Text] [Related]

  • 12. Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST® : SIMPLE USE).
    Park SW, Bebakar WM, Hernandez PG, Macura S, Hersløv ML, de la Rosa R.
    Diabet Med; 2017 Feb 29; 34(2):174-179. PubMed ID: 26773557
    [Abstract] [Full Text] [Related]

  • 13. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
    Philis-Tsimikas A, Astamirova K, Gupta Y, Haggag A, Roula D, Bak BA, Fita EG, Nielsen AM, Demir T.
    Diabetes Res Clin Pract; 2019 Jan 29; 147():157-165. PubMed ID: 30448451
    [Abstract] [Full Text] [Related]

  • 14. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
    Rodbard HW, Cariou B, Pieber TR, Endahl LA, Zacho J, Cooper JG.
    Diabetes Obes Metab; 2016 Mar 29; 18(3):274-80. PubMed ID: 26592732
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
    Zinman B, DeVries JH, Bode B, Russell-Jones D, Leiter LA, Moses A, Johansen T, Ratner R, NN1250-3724 (BEGIN:EASY AM) and NN1250-3718 (BEGIN:EASY PM) Trial Investigators.
    Lancet Diabetes Endocrinol; 2013 Oct 29; 1(2):123-31. PubMed ID: 24622318
    [Abstract] [Full Text] [Related]

  • 16. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
    Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Muñoz-Torres M, Donnet JP, Endahl L, Skjøth TV, Vaag A.
    Eur J Endocrinol; 2012 Aug 29; 167(2):287-94. PubMed ID: 22660026
    [Abstract] [Full Text] [Related]

  • 17. Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.
    Onishi Y, Yamada K, Zacho J, Ekelund J, Iwamoto Y.
    J Diabetes Investig; 2017 Mar 29; 8(2):210-217. PubMed ID: 27560769
    [Abstract] [Full Text] [Related]

  • 18. A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial.
    Liebl A, Davidson J, Mersebach H, Dykiel P, Tack CJ, Heise T.
    J Diabetes Sci Technol; 2013 Sep 01; 7(5):1328-36. PubMed ID: 24124961
    [Abstract] [Full Text] [Related]

  • 19. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
    Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth TV, Rana A, Mathieu C, BEGIN Once Long trial investigators.
    Diabet Med; 2013 Nov 01; 30(11):1298-304. PubMed ID: 23952326
    [Abstract] [Full Text] [Related]

  • 20. TREATMENT INTENSIFICATION WITH INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY: RANDOMIZED STUDY TO COMPARE SIMPLE AND STEP-WISE TITRATION ALGORITHMS.
    Gerety G, Bebakar WM, Chaykin L, Ozkaya M, Macura S, Hersløv ML, Behnke T.
    Endocr Pract; 2016 May 01; 22(5):546-54. PubMed ID: 26720250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.